DE&I leaders, executives, and professionals from the pharma, biotech, healthcare, and allied industries, are invited to the 2nd Advancing Diversity Equity & Inclusion (“ADEI”) In Pharma and Healthcare Summit. This online live-streaming event will be held on December 8-9, 2022. The agenda will guide you to move from awareness towards advocacy and action, as you build a culture of representation and inclusion for success in the workplace and clinical trial management. Professionals and industry experts from the medical realm gather on this forum to discuss and explore ways to attain success and improve the patient’s overall experience. This live-streaming event is attended by dignitaries and medical professionals from all over the world. They share valuable insights, get the know-how of trending healthcare issues, and analyze strategies for improved drug R&D, disease awareness, and clinical trial outcomes. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing b2b events. The global event company strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. Topics being covered at the summit include:

• Build workplace cultures that support different types of people, including LGBTQ
• Work towards the inclusion of disability and neurodiversity in the workplace
• Ensure better DE&I in clinical trials and drug development
• Discuss the best yardstick to measure the scope and durability of change
• Implement a recruiting strategy that aligns with your organization’s goals
• Explore the hurdles of incorporating DE&I in medical research and publishing
• What is the status of ERGs/BRGs in driving a culture of inclusion?
• Discuss the importance of creating a sense of belonging to the different facets of the society
• Initiate employee well-being programs that protect your initiatives and gains

This summit strongly emphasizes the need for inclusivity, belonging, and equality, and demonstrates how these factors positively impact drug R&D, disease awareness, and clinical trial outcomes. There will also be a highlight case study where Pfizer will share insights on the five-point strategy the organization implemented to successfully close the gender gap and reinforce equitable gender distribution. To learn more, please visit https://ibn.fm/pdC20.

• FuelPositive Corp. is a Canadian developer of clean energy solutions, focusing on an on-site system for producing hydrogen-dense green ammonia
• The company’s modular system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia — the amount needed to fertilize a 2,000-acre farm
• The system’s ability to grant end users greater energy independence as a climate-friendly resource is filling a market need at an opportune time as industries struggle to manage supply chain challenges created by COVID and the ongoing Russia-Ukraine war
• The module is being tested in a pilot project by Canadian farmers and recently became available for pre-sale orders

Clean energy technology developer FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is proving itself as a thought leader and innovator of climate-friendly farming solutions vital to global economies at a time when conflicts and supply chain interruptions are stressing needed resource markets. FuelPositive’s onsite, containerized, modular system for producing green, hydrogen-dense ammonia is designed to help the fertilizer-dependent agricultural industry and other end users who may want to produce ammonia or hydrogen fuel locally. The war in Ukraine has highlighted for many the need to ensure energy and agricultural independence because of the war’s disruptions of commodities supply chains for international product shipments that normally originate not only in Ukraine but Russia as well (https://ibn.fm/ZoX5I). Nancy Qian, a co-director of Northwestern University’s Global Poverty Research Lab and the Founding Director of China Econ Lab, noted in a recent editorial for Project Syndicate that Western nations are vulnerable to agricultural export problems that exceed the measure of the war’s disruptions. Those vulnerable nations, including the United States, she argued, would do well to increase production and reserves to mitigate the impact of any disruptions both for the sake of political maneuvering and to help stave off mass starvation in economically poorer countries (https://ibn.fm/ro7Di). “The global food system urgently needs to become more resilient for political and humanitarian reasons,” Qian stated. FuelPositive’s system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia, a hydrogen-dense resource that FuelPositive describes as the approximate amount needed for a 2,000-acre farm’s fertilizer needs. The modular model allows for additional systems to be added on for larger farms. Because the units are portable, fitting inside standard shipping containers, they can provide users’ needs onsite and reduce concerns about the vagaries of supply chain fulfillment. In August, the units became available for pre-sale for interested farmers. In Manitoba, Canadian farmers Tracy and Curtis Hiebert are preparing to use the modular system in the company’s first demonstration pilot project to evaluate its real-world performance over a one-year period. “The FuelPositive system will give us stability. That’s what we like about it. It’s stabilizing the supply and stabilizing the price,” Curtis Hiebert stated (https://ibn.fm/dSDz7). The initial base system price will be CA$950,000, although individual farm conditions may cause variability in the actual price, the company states. FuelPositive also expects that customers can lower their cost to acquire and operate the system by using government clean tech adoption programs. Carbon credits and tax incentives will further offset costs for its customers. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities
• BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies
• Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, recently presented at Recent Advances in Fermentation Technology (“RAFT”) 14, a conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”), which took place in Orlando, Florida. RAFT provides a platform for academic and industrial scientists to discuss the latest developments in fermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies at the Caribe Royale Orlando on November 8, 2022 (https://ibn.fm/ziT4B).

The RAFT presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nano-sized NanoAbs (aka VHH-antibodies and nanobodies). NanoAbs are a “bio-better” category of monoclonal antibodies (“mAbs”) providing several key advantages vs. currently available mAb therapies. These advantages include speed of discovery and production (important for newly emerging infectious diseases), smaller molecule (which suggests a better safety profile with fewer side effects), lower cost of production, greater thermostability (usually translates to longer shelf life), better ability to sustain shear forces (which allows for various routes of administration such as inhalation), much higher affinity to their molecular target (which could translate to lower required dose and possibly better efficacy at a given dose), and potentially enhanced patient convenience (e,g, self-administered inhalation at home, and lower adverse effects). The company’s lead NanoAb candidate for treating COVID-19 exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies.

BiondVax is uniquely positioned to advance nano-sized antibody innovation from R&D through commercialization via top-tier pharma leadership, extensive drug development expertise, in-house GMP biologics production facility, and collaboration with Max Planck and UMG.

BiondVax is developing additional NanoAbs to address diseases with large unmet medical needs and attractive commercial opportunities, likely beginning with psoriasis and asthma. Psoriasis is an autoimmune inflammatory disorder that results in the overproduction of skin cells, leading to an itchy, red skin condition that presents with inflammation, lesions, and plaque formation.

The psoriasis treatment market was valued at $24.33 billion globally in 2021 and is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, at a CAGR of 8.7% during the forecast period. According to the National Psoriasis Foundation (“NPF”) estimations, around 125 million patients globally suffered from psoriasis in 2020, with a prevalence between 1.5% and 5% in developed countries (https://ibn.fm/ciyBo).

BiondVax’s drug development expertise stems in part from its past experience with the development of a novel universal flu vaccine licensed from the Weizmann Institute of Science Lab of Professor Ruth Arnon, known for being the co-developer of Copaxone, Teva Pharmaceuticals’ block buster multiple sclerosis drug. During development of its prior vaccine candidate, BiondVax conducted seven phase 1/2 and phase 2 clinical trials in Israel, Europe, and the USA, and a seven-country pivotal Phase 3 trial conducted from 2018 to 2020 that was completed on-time and on-budget.

BiondVax is a public company traded on Nasdaq with the ticker BVXV. 21% of its shares are held by the cyber security mogul Marius Nacht, the founder of the world leading cyber security company CheckPoint (NASDAQ: CHKP).

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• While governmental leaders continue to work toward measurable climate progress, U.S.-based Correlate Infrastructure Partners Inc. is helping corporate clients attain ESG successes sought by investors
• The company recently reported that completion of construction milestones in contracted projects has netted it an 877 percent jump in revenues from Q2 to Q3, amounting to a 15,024 percent increase YOY
• CIPI’s efforts include helping clients achieve significant yet affordable change in their facilities’ utilities usage through improvements to mechanical, electrical, and plumbing processes, the addition of solar upgrades, water optimization, and other strategic measures

Nearly a decade has passed since world leaders agreed to pursue pollution reduction strategies to keep global temperature increases from peaking at more than 1.5 degrees Celsius above the planet-wide temperature peaks recorded nearly 300 years ago, and many climate policy makers who gathered this month for the latest United Nations-sponsored Conference of the Parties (“COP27”) climate change conference expressed concerns that not enough has been done to adhere to the agreement (https://ibn.fm/q0HDx). While U.S. President Joe Biden and Chinese President Xi Jinping declared Nov. 14 they would set aside disagreements over some of the countries’ policies enough to work together on fighting climate change, protecting global health and safeguarding access to food, many industries are also doing their part to show environmental, social and governance (“ESG”) responsibility in order to appeal to investors (https://ibn.fm/MK8lv). Correlate Infrastructure Partners (OTCQB: CIPI), a U.S. company that advises the commercial real estate industry (companies that develop and rent out commercial building properties) on potential ESG improvements and financing opportunities to make those improvements both workable and economical, is demonstrating its own success through a major jump in revenues from its operations. The company reported Nov. 14 that its quarterly income had grown 877 percent over the previous quarter from $236,690 to $2,312,577, due largely to completion of construction milestones in contracted projects. Year-over-year, Correlate Infrastructure’s revenues grew by nearly 15,024 percent. “We continue to make smart choices to optimize our organic project delivery based on a dynamic 2022 regulatory and supply chain landscape,” CEO Todd Michaels stated in the company’s Nov. 14 announcement (https://ibn.fm/1Jbdr). “The Inflation Reduction Act enacted in late August (by the federal government) provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content. While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023.” CIPI has another $16.2 million in unrecognized revenues in the pipeline for projects currently being installed at customer locations. All in all, the company currently has project opportunities valued at up to $194 million when projects in development are taken into consideration to include agreements that have been awarded but have not yet reached the executed contract stage. The figures indicate a measure of CIPI’s success in delivering advisory assistance on acquisitions and project development for environmentally friendly solutions, paired with infrastructure and financing resources. The company’s subsidiaries, Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design), analyze utilities usage and provide data-driven recommendations for improvements to HVAC, mechanical, electrical and plumbing processes, the addition of solar upgrades, water optimization and antimicrobial airflow, the strategic procurement of energy sources, vehicle electrification and master controls that provide intelligent oversight of any retrofits. The availability of government subsidies and the discovery of other financial incentives helps round out the benefits the companies provide. Correlate’s growth points to the rising demand for its expertise. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The online advertising ecosystem is transforming as governments worldwide ramp up regulations to rein in collection of consumers’ personal data
• Google’s Privacy Sandbox works toward the end of third-party cookies in Chrome, giving rise to a whole new privacy-compliant identity ecosystem
• As a company driven by the evolution of data privacy and its impact on consumers and companies, Reklaim appears well-positioned to capitalize on emerging market opportunities amid a paradigm shift happening with new privacy laws

User privacy is taking the online space by storm as consumers become increasingly conscious about how their online data is harvested and used. As a result, the online advertising architecture is about to transform, and companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) appear ready to seize the market opportunity that emerges amid intensified regulatory and consumer data protection scrutiny.

As consumers increase their presence in the digital space, the data they generate presents both an opportunity for brands to enhance their engagement with target audiences and a responsibility to keep that data safe. In a post-Cambridge Analytica world – a high-profile case exposing how Facebook used personal data from millions of profiles without their consent – consumers are increasingly wary about what data they share and with whom. According to Pew Research, an overwhelming majority of them – 72% – think their online activity is constantly tracked (https://ibn.fm/6AlKv).

Consumers seem to be constantly reminded that their heightened distrust may not be all that unwarranted as the lineup of companies coming into the spotlight due to their data protection failures expands. Most recently, it was Chegg Inc., an EdTech company providing services for high school and college students.

In its commitment to better protect Americans’ privacy and clamp down on businesses that collect personal information without consumers’ complete understanding, The Federal Trade Commission recently announced that it is taking action against Chegg Inc. for its lenient data security practices that exposed personal information about millions of its customers and employees, including, email addresses, passwords and Social Security numbers (https://ibn.fm/GE3H4).

Still, businesses and their digital marketing rely on collecting data on the online behavior of their target audiences. As a result, the sector has been on a winning streak (with revenue exploding at a record 35.4% in 2021) and is gearing up for another watershed year (https://ibn.fm/eOA4i). Without the free rein to collect consumers’ data, digital advertising needs a paradigm shift aligned with the new world in which consumers, regulators and technology companies require improved data privacy standards, which means the end of third-party cookies.

Previously, businesses could track consumers as they moved across multiple platforms and apps, collecting troves of information about their browsing habits. For example, Facebook aggregates a vast amount of data its users share about themselves as they engage with content and their connections. This information was then distributed to businesses that advertise on the platform so that they could deliver more relevant offers to their target audiences. With a bit of tech help called cookies – a piece of code stored in users’ browsers that collects data about them as they visit and interact with the web – businesses were able to learn about consumers’ online behavior. However, as it turns out, not all cookies are created equal. First-party cookies are limited to a single website, platform or app. Third-party cookies are designed to track users across the online space, allowing third parties to follow the entirety of a user’s internet activity and their online behavior and habits across practically the entire digital space.

It’s the third-party cookies that the latest privacy regulation aims to crack down on, and major tech companies play an essential role in these privacy-driven efforts. To protect users’ online privacy and help companies build thriving digital businesses, Google created Privacy Sandbox, a collaborative effort of the web community to develop privacy-first alternatives to third-party cookies. “Stage 1” of the transition will begin in late 2022, while support for third-party cookies is expected to be removed from Google’s Chrome browser in late 2023.

In a cookie-less reality, brands need to rethink their marketing approach and build advertising strategies around alternatives to third-party cookies. The new strategy relies on migration toward a zero- and first-party data approach, which presents a significant opportunity for innovation that allows businesses to mitigate regulatory risk while protecting and growing marketing revenue. This can improve customer satisfaction and enable marketers to make smarter decisions by reducing data silos (https://ibn.fm/mhInK).

Reklaim intends to step in as a company driven by the evolution of privacy and how it impacts consumers and businesses. Founded in 2018 and with headquarters in New York and offices in Toronto, Reklaim offers a privacy-compliant identity ecosystem. The company is focused on selling compliant, zero-party data to Fortune 500 brands and agencies that buy advertising, as well as platforms and data companies that sell data. Reklaim not only helps clients stay compliant amid the rapidly changing privacy market but also gives consumers visibility regarding how their data is collected and compensates them for its use. Positioned for the cookie-less future that is fast approaching, Reklaim seeks to empower consumers to take back control of their digital data that has been collected and sold for years without their explicit consent.

For more information, visit the company’s website at www.ReklaimYours.com.

NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon
• The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn
• Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced it had received Independent Review Board (“IRB”) approval for its planned human clinical nicotine study, NIC-H22-1 (https://ibn.fm/ONgsR). According to U.S. Food and Drug Administration (“FDA”) regulations, the receipt of the IRB approval by Lexaria means the company has taken the necessary steps to protect the rights and welfare of humans participating as subjects in its upcoming human study (https://ibn.fm/CQIHx). The pharmacokinetic (“PK”) randomized, double-blinded, cross-over study will comprise 36 human subjects who are current cigarette smokers. Each subject will visit the laboratory, where they will be dosed three times over a period of weeks. Only one of three nicotine pouch brands – DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match – will be administered during each visit. Subjective and objective evaluations will then follow. Through predetermined questionnaires, which will be used for each nicotine pouch, aiding in subjective evaluation, Lexaria will seek data related to throat burn, user experience, gastrointestinal experience, and more. Additionally, blood samples taken a total of eight times per visit will help in objective evaluations associated with the quantity of nicotine in the blood at various time points. At the same time, vital signs such as respiratory rate, heart rate, blood pressure, and temperature will also be collected. “This is a human clinical study to be conducted in the United States. It uses a DehydraTECH-oral nicotine powder that we have developed… The nicotine powder we will be using is one we already tested in animals last year – we had exceptionally strong results,” said CEO Chris Bunka in an interview with Proactive (https://ibn.fm/G7Tmx). “We believe, right now, that the Lexaria oral nicotine powder is the most advanced of its kind in the world, and we are going head-to-head with two of the top three leading brands of oral nicotine powders today: those manufactured by Swedish Match as well as by Altria. So, we are really excited for the study to commence.” Last October, Lexaria announced “outstanding results” from its NIC-A21-1 study evaluating oral nicotine absorption in animals. The company revealed that DehydraTECH needed only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. The results also showed that DehydraTECH-nicotine reached statistically significant peak blood plasma levels up to 10x higher overall than controls while still clearing from blood virtually as quickly as the controls. (https://ibn.fm/PuZTI). “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral formulations in this study,” said Chris Bunka at that time. “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.” Following receipt of the IRB approval, Lexaria expects to begin human dosing soon, with CEO Chris Bunka hinting during the Proactive interview, published November 3, that dosing will “have been completed in the next month or two and results [released] shortly thereafter.” The company hopes to evidence that processing purified nicotine with its patented DehydraTECH drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to the brands currently available on the market. Ultimately, and upon undergoing necessary evaluations, Lexaria hopes to license its technology in the oral pouch product category to offer better nicotine satiety and effectiveness, with the goal of one day rendering cigarette smoking and vaping as obsolete. This would potentially help stop the devastating consequences of cigarette smoking – the practice annually claims more than 480,000 lives in the United States (https://ibn.fm/kVjtw) and over 8 million lives globally (https://ibn.fm/9F3jG). Smoking is also linked to such maladies as cancer (trachea, lung, and bronchus), bronchitis, and coronary heart disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• EverGen commenced construction at its Core RNG Expansion Project at Fraser Valley Biogas; project is advancing on schedule and on budget with expected completion in Q1 2023
• Expansion is estimated to double FVB’s capacity to ~160,000 GJ of RNG per year; coupled with new long-term offtake agreement executed in current robust RNG market, it is expected to provide significant boost to company’s revenues and EBITDA
• As Canada’s early mover, EverGen seeks to consolidate assets across the country and leverage its expertise in designing and optimizing resilient facilities; with team that has seen more than a hundred RNG projects, company boasts a distinctive competitive advantage

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), Canada’s Renewable Natural Gas infrastructure platform that helps the fight against climate change and transition to a sustainable future, has announced that the company started construction work at its Core RNG Expansion Project at Fraser Valley Biogas –the Abbotsford, BC facility that combines anaerobic digestion and biogas upgrading to produce RNG. The project broke ground in Q3 2022 and is expected to complete in Q1 2023, when the facility will ramp up RNG production to the expanded capacity (https://ibn.fm/BgUzG). “We are proud of what our team has been able to achieve at FVB to date and pleased to see the project advancing on schedule and on budget,” said Chase Edgelow, CEO of EverGen. “All major mechanical equipment is on track for delivery and costs are within our C$13M-C$15M capital budget. These developments, coupled with the execution of a new long-term offtake agreement in a significantly stronger RNG market, will provide a substantial lift to our revenues and EBITDA.” The initial work is focused on an additional anaerobic digestor and upgrades of the existing feedstock processing system with a view to increase the facility’s production capacity. Upon the completion of this expansion project, the new RNG production volumes are expected to double the capacity of the facility to produce ~160,000 GJ of RNG per year. Established in 2011, Fraser Valley Biogas is Canada’s first agricultural digester to produce renewable natural gas. The RNG generated through this project that EverGen acquired in early 2021 is part of FortisBC’s program to supply renewable gas to homes and businesses. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced as part of the process (https://ibn.fm/BC9Z8). As an established independent renewable energy producer focused on acquiring, developing, owning and operating a portfolio of RNG waste-to-energy, and related infrastructure projects, EverGen is confident that it is heading to a catalyst-rich quarter. “We’re one of the first movers in Canada in terms of consolidating assets across the country. I think when we look at the RNG space today, it’s very similar to what the wind and solar space looked like, maybe ten or fifteen years ago. There’s a number of single project owners that are smaller businesses with greenfield projects. There are some existing assets that probably need more capital to be invested. We’ve taken an approach that we want to be a developer developing new projects from scratch, an owner and an operator of these facilities and to have a platform to be able to be in multiple provinces to share resources. That’s been our strategy and we’ve been effectively growing at a rapid pace with acquisitions that we’ve done in BC. This year we’ve done additional acquisitions in Alberta. We’ve got a significant development project, project Radius, the facilities in Ontario that give us our next leg of growth. We are looking at other provinces for other development projects that sit within our pipeline”, said Chase Edgelow describing the company’s growth plans (https://ibn.fm/ErAn8). “It’s about having technical expertise in the RNG space, so having the personnel that understands how to optimize these facilities, how to ensure you’re designing a facility that will be resilient. Our team has seen over a hundred projects in the space and that really helps us have an advantage with some of the smaller asset owners to be able to bring these projects into our portfolio to share the upside with them and to be able to continue to develop and grow across the country,” he concluded as he described the competitive advantage of the company that seeks to position itself as a leader in the RNG market. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research
• The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme
• The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine
• Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032

Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new cancer cases in the United States. In 2022, Cancer.gov estimates that there will be 25,050 new cases of brain and CNS cancers, with 18,280 patients dying from the disease (https://ibn.fm/JG0QS). To help raise awareness of these statistics, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO John Climaco participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run on November 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally, and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me,” Climaco commenting, underlining that supporting these patients, their journey, and challenges is both a priority and the core purpose of his company (https://ibn.fm/98YAN). “Across the globe, there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families, and to raise much-needed funds for research.” The Breakthrough for Brain Tumors(R) 5K Run took place in Hahamongna Watershed Park in Pasadena and will help The American Brain Tumor Association to create and provide patient and caregiver-focused programs throughout the year. These include patient and family meetings, the annual National Conference, and continuing to explore new programs and relationships in the area. Climaco was the single largest fundraiser for the event by raising nearly $5,000 and also placed 7th in his first-ever 5K race. More information the 5K can be found at https://ibn.fm/rfhM4. NetworkNewsAudio (“NNA”), which delivers additional visibility, recognition, and brand awareness in the investment community via distribution to thousands of syndications, recently featured CNS Pharmaceuticals’ recent announcement highlighting the activation of European clinical trial sites for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme (“GBM”). GBM is one of the most aggressive types of brain cancer, and Berubicin is the first anthracycline to appear to cross the blood-brain barrier. The results from this pivotal trial will compare Berubicin to a current standard of care, Lomustine, with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine (https://ibn.fm/7ZWYY). The global brain tumor treatment market was valued at $2,946 million in 2022. This value is expected to grow at a CAGR of 7.2% over the forecast period, resulting in a valuation of $5,904 million by 2032. Medication advancements and the efficiency of treatments are expected to be a driving factor for growth within the industry – with more pharmaceutical R&D spending also expected (https://ibn.fm/ZecMG). CNS has been granted FDA Fast Track Designation for Berubicin, enabling more frequent interactions with the FDA for guidance on expediting the development and review process. The company has also received an Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Arizona Metals owns 100% of two copper and gold exploration projects in mining-friendly Arizona
• Both projects have excellent infrastructure, including roads, available power and water access
• Only 3% of the prospectively mineralized trend that hosts the high-grade Kay Mine Deposit has been drilled
• The company had $60 million in cash as of June 30, 2022, to complete Phase 2 and begin Phase 3 drilling at the Kay Mine

Arizona Metals (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County. The company in October 2022 received permit approval from the Bureau of Land Management (“BLM”) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023. The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit. Arizona Metals Corp. is based in Toronto, Canada. Projects Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Market Opportunity The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing. The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices. Management Team Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada. David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School. Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services. For more information, visit the company’s website at www.ArizonaMetalsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• In 2021, a third of the world’s assets under management, including the money of growing numbers of huge public pension funds, were invested according to ESG principles, with the year posting the highest expenditure on ESG initiatives globally
• Correlate recognizes the growing need for businesses to achieve ESG goals and is looking to meet this demand by offering a complete suite of proprietary clean energy assessment solutions, specifically for the commercial real estate industry
• Its unique data-driven approach draws from proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network that has earned it an opportunity pipeline of over $100 million in commercial projects and over $20 million in awarded backlog
• With the cost to hit the UN sustainability goals having risen by 25% over the past year, Correlate is looking to offer an affordable, viable solution, allowing consumers to successfully draw the benefits associated with renewable energy
• The company is also laying the groundwork for the imminent transition to renewable energy by making retrofitting as easy, affordable, and seamless as possible

2021 saw the highest expenditure on Environmental, Social, and Governance (“ESG”) initiatives globally at $649 billion, according to Morningstar Direct. It was further estimated that during that year, a third of the world’s assets under management, including the money of growing numbers of huge public pension funds, were invested according to ESG principles (https://ibn.fm/3r7ES).

The focus on this sector reflected businesses’ acknowledgment of what the planet needs, particularly in the wake of climate change, widening inequality, and other social problems. As businesses continue exploring how to achieve their ESG goals, Correlate Infrastructure Partners (OTCQB: CIPI) offers an affordable and profitable ESG-related energy solution targeted at both companies and organizations.

Correlate, a driver of highly cost-effective energy use optimization solutions, through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment solutions for the commercial real estate industry. It further develops and finances renewable energy projects that allow these investment properties to operate more efficiently from an energy and financial standpoint.

As more companies recognize the significance of ESG goals and achieving them, Correlate is expanding its list of product and service offerings, focusing on renewable solar energy generation, electric vehicle (“EV”) infrastructure, and intelligent efficiency measures. Its unique data-driven approach draws from proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network designed to help building owners profit from fully-funded, turnkey decarbonization and facility health programs.

This approach has earned Correlate an opportunity pipeline of over $100 million in commercial projects, with over $20 million in awarded backlog, a clear indication of how well-received its ESG solutions are by the target market.

With the cost to hit the United Nations (“UN”) sustainability goals having risen by 25% to $176 trillion over the past year, there is a growing need to make ESG-related systems and infrastructure accessible and affordable by the masses. Furthermore, rising economic pressures have also dealt a blow to the progress on several Sustainable Development Goals (“SDGs”), which is further impacting the adoption of ESG measures and infrastructure (https://ibn.fm/HKVBj).

Correlate recognizes the challenge and is out to offer a viable solution targeted toward business owners, companies, and even real estate owners. The company is confident that with its approach, more consumers will adopt renewable energy and even draw the benefits associated with it, both in the short-term and the long term.

Correlate is also laying the groundwork for the imminent transition towards renewable energy in the United States and globally. It is making retrofitting as easy, affordable, and seamless as possible, and by doing so, it is allowing more businesses to shift to renewable energy sources and achieve their ESG goals. It is also proving instrumental in highlighting the value of ESG and the importance of renewable energy in achieving associated ESG goals.

For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI